Literature DB >> 35106677

The role of imaging features and resection status in the survival outcome of sporadic optic pathway glioma children receiving different adjuvant treatments.

Zhi-Ming Liu1, Chi-Hyi Liao1, Xu An1, Wen-Tao Zhou1, Zhen-Yu Ma1, Wei Liu1, Yong-Ji Tian2,3.   

Abstract

Optic pathway glioma (OPG) is a rare brain tumor affecting children, with no standard treatment strategy. This study described the sporadic OPG survival outcomes after surgical treatment and analyzed the role of imaging features and resection status in children receiving different adjuvant treatments. This retrospective study included 165 OPG patients whose clinical information were obtained from the hospital record system. Tumor volume and residual tumor volume were calculated by delineating the lesion area. Kaplan-Meier method and Cox proportional hazards model were conducted to analyze the independent prognosis factor. A total of 165 patients were included in this study. Respectively, the 5-year overall survival (OS) and progression-free survival (PFS) were 87.58% and 77.87%. Residual tumor size and first adjuvant treatment (AT) after surgery were both associated with PFS. In patients with small-size residual tumors, there was no significant difference in PFS between the AT treatment groups. Moreover, age, exophytic cystic components, leptomeningeal metastases, and AT were associated with OS. In patients with exophytic cystic components and those with leptomeningeal metastases, there was no significant difference in OS. Our results revealed that OPG patients could avoid or defer AT by maximized resection. Age ≤ 2 years was a disadvantageous factor for OS. Patients with exophytic cystic components were more likely to benefit from primary surgery, and CT or RT was not beneficial for these patients. Patients with leptomeningeal metastases had a poor prognosis regardless of the treatment they received. Future prospective clinical studies are needed to develop more effective treatment regimens.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Adjuvant treatment; Cystic components; Debulking surgery; Imaging; Optic pathway glioma

Year:  2022        PMID: 35106677     DOI: 10.1007/s10143-022-01743-1

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  25 in total

1.  Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.

Authors:  Joann L Ater; Tianni Zhou; Emiko Holmes; Claire M Mazewski; Timothy N Booth; David R Freyer; Ken H Lazarus; Roger J Packer; Michael Prados; Richard Sposto; Gilbert Vezina; Jeffrey H Wisoff; Ian F Pollack
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Institutional Review of Mortality in 5434 Consecutive Neurosurgery Patients: Are We Improving?

Authors:  Aladine A Elsamadicy; Amanda Sergesketter; John H Sampson; Oren N Gottfried
Journal:  Neurosurgery       Date:  2018-12-01       Impact factor: 4.654

3.  Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome.

Authors:  Stephanie E Combs; Daniela Schulz-Ertner; Dimos Moschos; Christoph Thilmann; Peter E Huber; Jürgen Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

4.  Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).

Authors:  A K Gnekow; R-D Kortmann; T Pietsch; A Emser
Journal:  Klin Padiatr       Date:  2004 Nov-Dec       Impact factor: 1.349

5.  Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care.

Authors:  Fred G Barker; William T Curry; Bob S Carter
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

6.  Management of optic pathway and chiasmatic-hypothalamic gliomas in children with radiation therapy.

Authors:  H S Erkal; M Serin; A Cakmak
Journal:  Radiother Oncol       Date:  1997-10       Impact factor: 6.280

Review 7.  Optic pathway gliomas: a review.

Authors:  Iris Fried; Uri Tabori; Tarik Tihan; Arun Reginald; Eric Bouffet
Journal:  CNS Oncol       Date:  2013-03

8.  Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology.

Authors:  Astrid K Gnekow; Fabian Falkenstein; Stephan von Hornstein; Isabella Zwiener; Susanne Berkefeld; Brigitte Bison; Monika Warmuth-Metz; Pablo Hernáiz Driever; Niels Soerensen; Rolf-D Kortmann; Torsten Pietsch; Andreas Faldum
Journal:  Neuro Oncol       Date:  2012-08-31       Impact factor: 12.300

9.  A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report.

Authors:  Astrid K Gnekow; David A Walker; Daniela Kandels; Susan Picton; Jacques Grill; Tore Stokland; Per Eric Sandstrom; Monika Warmuth-Metz; Torsten Pietsch; Felice Giangaspero; René Schmidt; Andreas Faldum; Denise Kilmartin; Angela De Paoli; Gian Luca De Salvo
Journal:  Eur J Cancer       Date:  2017-06-22       Impact factor: 9.162

10.  Current and emerging treatment strategies for children with progressive chiasmatic-hypothalamic glioma diagnosed as infants: a web-based survey.

Authors:  Amedeo A Azizi; Antoinette Y N Schouten-van Meeteren
Journal:  J Neurooncol       Date:  2017-10-25       Impact factor: 4.130

View more
  1 in total

1.  Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1.

Authors:  Laura-Nanna Lohkamp; Patricia Parkin; Allan Puran; Ute Katharina Bartels; Eric Bouffet; Uri Tabori; James Thomas Rutka
Journal:  Front Surg       Date:  2022-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.